Literature DB >> 9886845

Transcriptional interferences between normal or mutant androgen receptors and the activator protein 1--dissection of the androgen receptor functional domains.

J M Lobaccaro1, N Poujol, B Térouanne, V Georget, S Fabre, S Lumbroso, C Sultan.   

Abstract

We investigated the interferences of the normal or mutated androgen receptor with the activator protein-1 (AP-1) by assessing their effects on transcriptional activity in CV-1 cells. A luciferase reporter gene was constructed downstream from either a promoter for the mouse vas deferens protein, or a trimerized 12-O-tetradecanoyl phorbol-13-acetate-response element site whose transcriptions are activated by androgen and 12-O-tetradecanoyl phorbol-13-acetate, a potent AP-1 activator. The blockade of dephosphorylation by protein phosphatases identifies the protein phosphatases that modulate the AP-1/androgen receptor cross-talk. Using engineered or naturally occurring androgen receptor mutants that are responsible for complete or partial androgen insensitivity syndromes, we defined the subregions involved in the cross-talk of the androgen receptor with the AP-1 factors. First, it appears that the 188 first amino acids of the N-terminal domain of the androgen receptor are necessary to obtain a full transrepression. Second, a functional and intact ligand binding domain is critical for the modulation of androgen/AP-1 pathway interactions. Third, normal DNA binding capacity of the androgen receptor is not required. Two mutants at positions 568 and 581 of the DNA binding domain demonstrate that the transactivation and transrepression functions of the androgen receptor can be dissociated. Collectively, these data indicate that several segments of the androgen receptor are involved in cross-talk with the AP-1 pathway. Mutations within the DNA binding domain of the androgen receptor highly impair these interferences.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886845     DOI: 10.1210/endo.140.1.6418

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells.

Authors:  Huiqing Yuan; Charles Y F Young; Yuanyuan Tian; Zhifang Liu; Mengye Zhang; Hongxiang Lou
Journal:  Mol Cell Biochem       Date:  2010-02-11       Impact factor: 3.396

2.  Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.

Authors:  Michèle Manin; Silvère Baron; Karine Goossens; Claude Beaudoin; Claude Jean; Georges Veyssiere; Guido Verhoeven; Laurent Morel
Journal:  Biochem J       Date:  2002-09-15       Impact factor: 3.857

3.  Transcriptional activity of c-Jun is critical for the suppression of AR function.

Authors:  Chih-Chao Hsu; Chang-Deng Hu
Journal:  Mol Cell Endocrinol       Date:  2013-03-21       Impact factor: 4.102

4.  Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa.

Authors:  Frauke Coppieters; Bart P Leroy; Diane Beysen; Jan Hellemans; Karolien De Bosscher; Guy Haegeman; Kirsten Robberecht; Wim Wuyts; Paul J Coucke; Elfride De Baere
Journal:  Am J Hum Genet       Date:  2007-05-24       Impact factor: 11.025

5.  The homeodomain protein HOXB13 regulates the cellular response to androgens.

Authors:  John D Norris; Ching-Yi Chang; Bryan M Wittmann; Rebecca S Kunder; Huaxia Cui; Daju Fan; James D Joseph; Donald P McDonnell
Journal:  Mol Cell       Date:  2009-11-13       Impact factor: 17.970

Review 6.  In vitro reporter assays for screening of chemicals that disrupt androgen signaling.

Authors:  Gargi Bagchi Bhattacharjee; S M Paul Khurana
Journal:  J Toxicol       Date:  2014-11-09

7.  The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer.

Authors:  Yongjun Quan; Xiaodong Zhang; William Butler; Zhen Du; Mingdong Wang; Yuexin Liu; Hao Ping
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.